http://www.zibb.com/healthcare/theme/cq/Bristol+Myers+Squibb+Company Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Mon, 23 Nov 2009 16:19:48 GMTMon, 23 Nov 2009 16:19:48 GMT608831http://www.zibb.com/healthcare/theme/cq/Bristol+Myers+Squibb+Company http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://finance.yahoo.com/news/BristolMyers-extends-apf-1935439253.html?x=0&.v=1NEW YORK (AP) -- Drugmaker Bristol-Myers Squibb Co. and Asterand PLC are extending a research collaboration for up to three years, Asterand said Monday.Asterand, with officeshttp://finance.yahoo.com/news/BristolMyers-extends-apf-1935439253.html?x=0&.v=1Bristol Myers Squibb CompanyMon, 23 Nov 2009 16:19:48 GMThttp://www.biospace.com/news_story.aspx?StoryID=163628&full=1PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY - News) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S.http://www.biospace.com/news_story.aspx?StoryID=163628&full=1Bristol Myers Squibb CompanyMon, 23 Nov 2009 12:00:00 GMThttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=10822-Completes Major Phase in Company’s BioPharma Transformation -Provides Bristol-Myers Squibb Shareholders an Option for a Tax-Free Exchange -Expected to be Accretive to EPS Beginning in 2010 -Reflects Strength and Sustainability of BioPharhttp://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=10822Bristol Myers Squibb CompanyTue, 17 Nov 2009 01:00:00 GMThttp://seattle.bizjournals.com/seattle/stories/2009/11/09/daily15.html?ana=yfcpcAlder Biopharmaceuticals and Bristol-Myers Squibb sign deal worth up to $1Bhttp://seattle.bizjournals.com/seattle/stories/2009/11/09/daily15.html?ana=yfcpcBristol Myers Squibb CompanyTue, 10 Nov 2009 17:05:18 GMThttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3562321&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=3562321&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2303731850%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBiotechnology and Pharmaceutical Industry Search Find Companies, News, Events, Jobs, Directoryhttp://www.bioportfolio.co.uk/cgi-bin/dialogserver.exe?CMD=hit.displayMdoc&ID=3562321&HITNO=14&MSIZE=1000&LANGUAGE=en&FILE=doc.NEWSFEED&SAVEQUERY00=biotechnology%20pharmaceutical&SAVEPROP00=L%3den&SAVEDB=news&SAVEORGANISE_CODED=R%3adate&R=3562321&THISHREF=http%3a//c.moreover.com/click/here.pl%3fz2303731850%26amp%3bz%3d950242273&THEHOST=site+d.moreover.comBristol Myers Squibb CompanyMon, 02 Nov 2009 06:55:24 GMThttp://seekingalpha.com/article/168319-bristol-myers-squibb-co-q3-2009-earnings-call-transcript?source=feedBristol-Myers Squibb Co.(BMY)Q3 2009 Earnings CallOctober 22, 2009 10:30 am ET<ahttp://seekingalpha.com/article/168319-bristol-myers-squibb-co-q3-2009-earnings-call-transcript?source=feedBristol Myers Squibb CompanyThu, 22 Oct 2009 20:50:20 GMThttp://www.pharmaceutical-business-review.com/news/rexahn_teva_agree_to_close_on_license_agreement_090917Rexahn Pharmaceuticals (Rexahn) has reached an agreement to close on its previously announced licensing and stock purchase agreements with Teva Pharmaceutical (Teva) for the development of its novel anti-cancer compound, RX-3117.http://www.pharmaceutical-business-review.com/news/rexahn_teva_agree_to_close_on_license_agreement_090917Bristol Myers Squibb CompanyThu, 17 Sep 2009 00:00:00 GMThttp://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/08-30-2009/0005084927&EDATE=PARIS, and PRINCETON, N.J., Aug. 30 /PRNewswire/ -- Today, the OASIS study group will present initial results of the CURRENT-OASIS 7 clinical trial at the European Society of Cardiology congress in Barcelona.http://news.prnewswire.com/ViewContent.aspx?ACCT=109&STORY=/www/story/08-30-2009/0005084927&EDATE=Bristol Myers Squibb CompanySun, 30 Aug 2009 06:00:00 GMThttp://www.pharmamanufacturing.com/industrynews/2009/139.html?CMP=ILC-rssA US court granted preliminary approval to a $125-million settlement reached in a shareholder lawsuit against Bristol-Myers Squibb regarding the company's attempts to resolve a patent dispute with Apotex over Plavix (clopidogrel), according to court documents.http://www.pharmamanufacturing.com/industrynews/2009/139.html?CMP=ILC-rssBristol Myers Squibb CompanyWed, 19 Aug 2009 07:00:59 GMThttp://www.genengnews.com/news/bnitem.aspx?name=52843995Bristol-Myers Squibb (BMS) is initially paying Ensemble Discovery $5 million to discover and develop drug candidates against up to eight targets. Ensemble will receive another $7.5http://www.genengnews.com/news/bnitem.aspx?name=52843995Bristol Myers Squibb CompanyWed, 15 Apr 2009 00:00:00 GMThttp://contractservices.pharmaceutical-business-review.com/news/bristol_myers_squibb_extends_us_agreement_with_otsuka_090409In addition, the companies have established oncology collaboration for two Bristol-Myers Squibb products - Sprycel (dasatinib) and Ixempra (ixabepilone). Under terms of the agreement Bristol-Myers Squibb will pay Otsuka an up-front cash payment of $400 million.http://contractservices.pharmaceutical-business-review.com/news/bristol_myers_squibb_extends_us_agreement_with_otsuka_090409Bristol Myers Squibb CompanyThu, 09 Apr 2009 03:32:40 GMThttp://www.fda.gov/cder/ogd/AG_Listing.htmNote: This list of authorized generic drugs (AGs) was created from a manual review of FDA’s database of annual reports submitted to the FDA since January 1, 1999 by sponsors of new drug applications (NDAs).http://www.fda.gov/cder/ogd/AG_Listing.htmBristol Myers Squibb CompanyFri, 27 Mar 2009 11:40:00 GMThttp://www.marketwatch.com/news/story/myriad-pfizer-novo-nordisk-lead/story.aspx?guid=%7B2776506F%2D9261%2D4925%2D824A%2D8E20F008B073%7D&siteid=yhoofMyriad Genetics, Pfizer Inc. and Novo Nordisk A/S are the standout gainers as the broader market reacts positively to news that U.S. durable-goods orders for February came in significantly higher than expected.http://www.marketwatch.com/news/story/myriad-pfizer-novo-nordisk-lead/story.aspx?guid=%7B2776506F%2D9261%2D4925%2D824A%2D8E20F008B073%7D&siteid=yhoofBristol Myers Squibb CompanyWed, 25 Mar 2009 16:39:00 GMThttp://www.cnbc.com/id/29635274/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahooThe Biotechnology Industry Organization just announced that Sir Elton will be the keynote speaker at the 2009 BIO International Convention in Atlanta, the superstar's American hometown.http://www.cnbc.com/id/29635274/site/14081545?__source=yahoo%7Cheadline%7Cquote%7Ctext%7C&par=yahooBristol Myers Squibb CompanyWed, 11 Mar 2009 15:03:51 GMThttp://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=157045590Recent talks are about the recession, economic downturn, credit crunch and so on. However, the pharma giant Pfizer made a remarkable start in 2009. Pfizer acquires its rival big pharma company Wyeth for about $68bn for stock and cash. This acquisition is said to be the one of the biggest in thehttp://www.frost.com/prod/servlet/market-insight-top.pag?Src=RSS&docid=157045590Bristol Myers Squibb CompanyThu, 29 Jan 2009 00:00:00 GMThttp://www.fool.com/investing/dividends-income/2009/01/15/for-pfizer-a-big-buy-could-be-a-big-mistake.aspx(NYSE: PFE), is getting plenty of unsolicited advice from analysts and self-proclaimed financial experts. They say Pfizer must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Here's my advice: Don't do it.http://www.fool.com/investing/dividends-income/2009/01/15/for-pfizer-a-big-buy-could-be-a-big-mistake.aspxBristol Myers Squibb CompanyThu, 15 Jan 2009 17:49:31 GMThttp://www.bizjournals.com/sanjose/stories/2008/12/08/daily104.html?ana=from_rssExelixis will receive the upfront payment for the development and commercialization rights to both programs. The payment it will get next year will cover licenses. The first compound, XL-184, is focused on treating medullary thyroid cancer and is Exelixis’ only drug in Phase III trials.http://www.bizjournals.com/sanjose/stories/2008/12/08/daily104.html?ana=from_rssBristol Myers Squibb CompanyFri, 12 Dec 2008 21:46:44 GMThttp://uk.reuters.com/article/healthNews/idUKTRE4BB6E620081212?feedType=RSS&feedName=healthNewsWASHINGTON (Reuters) - U.S. health regulators are questioning whether clinical trials proposed by ImClone Systems and Amgen Inc will be adequate to show that patients with a certain type of gene are morehttp://uk.reuters.com/article/healthNews/idUKTRE4BB6E620081212?feedType=RSS&feedName=healthNewsBristol Myers Squibb CompanyFri, 12 Dec 2008 19:50:16 GMThttp://biz.yahoo.com/bw/081212/20081212005480.html?.v=1Sanofi-Aventis and Bristol-Myers Squibb Prevail before the U.S. Court of Appeals for the Federal Circuit in the U.S Plavix® Patent Infringement Case. - PARIS & NEW YORK--(BUSINESS WIRE)--Sanofi-aventis (Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY) and Bristol-Myers Squibb (New York: NYSE:http://biz.yahoo.com/bw/081212/20081212005480.html?.v=1Bristol Myers Squibb CompanyFri, 12 Dec 2008 17:30:00 GMThttp://www.istockanalyst.com/article/viewarticle/articleid/2876285Bristol-Myers Squibb Company (NYSE: BMY) has agreed to ink a deal with biotechnology company Exelixis Inc. (NASDAQ: EXEL) to jointly develop two experimental cancer drugs.[More...]http://www.istockanalyst.com/article/viewarticle/articleid/2876285Bristol Myers Squibb CompanyFri, 12 Dec 2008 13:27:00 GMThttp://www.astrazeneca.com/?itemId=4369714AstraZeneca and Bristol-Myers Squibb Announce Expansion of Worldwide Collaboration to Develop and Commercialise Dapagliflozin in Japanhttp://www.astrazeneca.com/?itemId=4369714Bristol Myers Squibb CompanyMon, 08 Dec 2008 12:00:37 GMThttp://sanfrancisco.bizjournals.com/sanfrancisco/stories/2008/11/03/daily114.html?ana=yfcpcExelixis will take a $3.3 million restructuring-related charge in the fourth quarter, related to one-time “termination benefits.” The restructuring plan will be completed during the first quarter of 2009.http://sanfrancisco.bizjournals.com/sanfrancisco/stories/2008/11/03/daily114.html?ana=yfcpcBristol Myers Squibb CompanySat, 08 Nov 2008 12:05:30 GMThttp://triangle.bizjournals.com/triangle/stories/2008/11/03/daily37.html?ana=yfcpcIcagen (Nasdaq: ICGN) said it lost $3.6 million, or 8 cents per diluted share, in the quarter. A year earlier, the company earned $5.6 million, or 13 cents per diluted share. Revenue sank, to $3.1 million, from $12.9 million a year earlier.http://triangle.bizjournals.com/triangle/stories/2008/11/03/daily37.html?ana=yfcpcBristol Myers Squibb CompanyFri, 07 Nov 2008 10:06:04 GMThttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/081102/20081102005040.html?.v=1New Data Suggest Long-Term Treatment with BARACLUDE(R) (entecavir) May Reduce Liver Damage Caused by Chronic Hepatitis B. - SAN FRANCISCO--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY - News) today announced data from two separate cohort evaluations, in which long-term treatment withhttp://us.rd.yahoo.com/finance/news/rss/story/*http://biz.yahoo.com/bw/081102/20081102005040.html?.v=1Bristol Myers Squibb CompanySun, 02 Nov 2008 16:00:00 GMThttp://community.investopedia.com/news/IA/2008/Missing-Forest-Labs-For-The-Trees-FRX-PFE-MRK1027.aspx?partner=YahooSAForest Labs (NYSE:FRX) is admittedly a different kind of pharmaceutical company. It doesn't have the product lineup or pipeline of a company like Pfizer (NYSE:PFE) or Sanofi-Aventis (NYSE:SNY), nor does it have the basic from-the-ground-up R&D capability of most large drug companies.http://community.investopedia.com/news/IA/2008/Missing-Forest-Labs-For-The-Trees-FRX-PFE-MRK1027.aspx?partner=YahooSABristol Myers Squibb CompanyMon, 27 Oct 2008 21:14:29 GMT